


Docket No. 210119US0CONT



Image

1652
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 09/895,072

GAU: 1652

FILED: July 2, 2001

EXAMINER: Patterson

FOR: METHODS FOR PRODUCING HIGHLY PHOSPHORYLATED LYSOSOMAL HYDROLASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

02/17/2004 DEMMANU1 00000022 09895072

01 FC:1806

180.00 OP



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAYER & NEUSTADT, P.C.


Richard L. Chinn, Ph.D.

Registration No. 34,305

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Docket No. 210119US0CONT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 09/895,072

GAU: 1652

FILED: July 2, 2001

EXAMINER: Patterson

FOR: METHODS FOR PRODUCING HIGHLY PHOSPHORYLATED LYSOSOMAL HYDROLASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Richard L. Chinn, Ph.D.


Registration No. 34,305



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.
Registration No. 45,518

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
210119US0CONTSERIAL NO.
09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
William M. CANFIELDFILING DATE
July 2, 2001GROUP
1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	99/31117	06/24/99	WIPO		
	AP					
	AQ					
	AR					


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AS	Ke-Wei ZHAO, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphotransferase", Glycobiology, Vol. 2, no. 2, pp. 119-125, 1992	
	AT	Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", DNA Research, Vol. 6, pp. 337-345, 1999	
	AU	XP-002226188, "KIAA1208 protein (Fragment)", From Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", DNA Research, Vol. 6, pp. 337-345, 1999	
	AV	XP-002226187, "Basic domain/leucine zipper transcription factor (Fragment), From CORDES, et al., "The mouse segmentation gene <i>kr</i> encodes a novel basic domain-leucine zipper transcription factor" (1994), Cell, Vol. 7, No. 9, pp.1025-1034	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

210119US0CONT

SERIAL NO.

09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

July 2, 2001

GROUP

1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BO					
	BP					
	BQ					
	BR					
	BS					
	BT					
	BU					
	BV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

BW	✓	Karen Gheesling MULLIS, et al., "Purification and Kinetic Parameters of Bovine Liver N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", The Journal of Biological Chemistry, Vol. 269, No. 3, Issue of January 21, pp. 1718-1726, 1994
BX	✓	Jin Kyu LEE, et al., "Purification and Characterization of Human Serum N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", Archives of Biochemistry and Biophysics, Vol. 319, No. 2, June 1, pp. 413-425, 1995
BY	✓	Theodore PAGE, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase", Glycobiology, Vol. 6, no. 6, pp. 619-626, 1996
BZ	✓	Thomas J. BARANSKI, et al., "Lysosomal Enzyme Phosphorylation", The Journal of Biological Chemistry, Vol. 267, No. 32, Issue of November 15, pp. 23342-23348, 1992
		<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
210119US0CONTSERIAL NO.
09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
William M. CANFIELDFILING DATE
July 2, 2001GROUP
1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						
	CL						
	CM						
	CN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CO					
	CP					
	CQ					
	CR					
	CS					
	CT					
	CU					
	CV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

CW	Elva TIKKANEN, et al., "Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase", The EMBO Journal, vol. 16, No. 22, pp. 6684-6693, 1997	<input type="checkbox"/> Additional References sheet(s) attached
CX	Fumito MATSUURA, et al., "Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells", Glycobiology, vol. 8, no. 4, pp. 329-334, 1998	
CY	Shiroh MAGUCHI, et al., "Elevated Activity and Increased Mannose-6-phosphate in the Carbohydrate Moiety of Cathepsin D from Human Hepatoma", Cancer Research, Vol. 48, pp. 362-367, January 15, 1988	
CZ	Norman W. Barton, et al., "Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 1913-1916, March 1990	

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

210119US0

SERIAL NO.

09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

July 2, 2001

GROUP

1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						
	DL						
	DM						
	DN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DN					
	DP					
	DQ					
	DR					
	DS					
	DT					
	DU					
	DV					


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	DW	R.O. BRADY, et al., "Modifying Exogenous Glucocerebrosidase for Effective Replacement Therapy in Gaucher Disease", J. Inher. Metab. Dis., Vol. 17, (1994), pp. 510-519	
	DX	Emil D. KAKKIS, et al., "Overexpression of the Human Lysosomal Enzyme α -L-Iduronidase in Chinese Hamster Ovary Cells", Protein Expression and Purification, Vol. 5, (1994), pp. 225-252	
	DY	Ke-Wei ZHAO, et al., "Carbohydrate Structures of Recombinant Human α -L-Iduronidase Secreted by Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, Vol. 272, No. 36, Issue of September 5, 1997, pp. 22758-22765	
	DZ	Robin J. ZIEGLER, et al., "Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer", Human Gene Therapy, Vol. 10, pp. 1667-1682, (July 1, 1999)	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

PRIORITY DOCKET NO.

210119US0

SERIAL NO.

09/895,072

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

July 2, 2001

GROUP

1652

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
	EC						
	ED						
	EE						
	EF						
	EG						
	EH						
	EI						
	EJ						
	EK						
	EL						
	EM						
	EN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	EN					
	EP					
	EQ					
	ER					
	ES					
	ET					
	EU					
	EV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	EW	Huaichang SUN, et al., "Retrovirus Vector-Mediated Correction and Cross-Correction of Lysosomal α -Mannosidase Deficiency in Human and Feline Fibroblasts", Human Gene Therapy, Vol. 10, pp. 1311-1319, (May 20, 1999)				
	EX	Alj REUSER, et al., "Lysosomal storage diseases: cellular pathology, clinical and genetic heterogeneity, therapy", Ann Biol Clin., Vol. 52, (1994), pp. 721-728				
	EY					
	EZ					<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.